Avastin lung cancer sBLA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Genentech is requesting priority review of an sBLA supporting a first-line non-small cell lung cancer claim for Avastin (bevacizumab). The new claim, submitted April 10, is based on an 878-patient trial that showed a 25% improvement in overall survival for patients on Avastin plus paclitaxel and carboplatin versus chemotherapy alone. Another sBLA in metastatic breast cancer is slated for submission during the second quarter. In October, Genentech discontinued an Avastin trial in ovarian cancer following reports of high gastrointestinal perforation rates (1Pharmaceutical Approvals Monthly October 2005, p. 14)...
You may also be interested in...
Genentech Stops Avastin Ovarian Cancer Trial Enrollment After GI Perforations
Genentech is discontinuing enrollment of a Phase II study of Avastin (bevacizumab) in platinum-refractory ovarian cancer patients due to an excessively high rate of reported gastrointestinal perforations
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.